医脉通导读本项纳入随机对照试验的系统综述和meta分析显示，糖尿病或肥胖患者使用GLP-1受体激动剂（如，利拉鲁肽、司美格鲁肽）时，发生自杀自伤相关不良事件的风险较安慰剂无显著升高。肥胖是人类健康的大敌。作为肥胖的标准治疗手段之一，减重手术与自杀风险 ...

本研究聚焦帕西瑞肽诱导的高血糖问题，通过体内外实验探究其机制，发现GLP-1分泌受阻是关键，GLP-1类似物治疗效果显著优于DPP-4抑制剂，为糖尿病治疗提供新思路 帕西瑞肽是一种用于治疗肢端肥大症等疾病的药物，但其常引发严重的高血糖问题，目前尚无基于 ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

Diabetes. 2013;62(2):373-381. Since it is known that the activity of DPP-4 is primarily responsible for the rapid degradation of GLP-1, using the drug sitagliptin we assessed how inhibition of DPP ...

1月10日，中国国家药品监督管理局（NMPA）官网发布公告，批准石药集团研发的创新型口服DPP-4抑制剂普卢格列汀片在中国上市。 该药适用于改善成人 ...

Please provide your email address to receive an email when new articles are posted on . GLP-1s reduced depression risk vs. DPP-4 inhibitors but not SGLT2 inhibitors. However, both GLP-1s and SGLT2 ...

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...

The use of GLP-1 receptor agonists, like semaglutide, to treat type 2 diabetes is not associated with an increased risk of ...

A large-scale study analyzing data from over 60 million patients finds no evidence that GLP-1 receptor agonists increase suicidality risk in type 2 diabetes patients, challenging previous safety ...

FRIDAY, Feb. 28, 2025 (HealthDay News) -- GLP-1 drugs like Ozempic/Wegovy don’t increase a person’s risk of suicidal actions or thoughts, a new study has concluded. Earlier research had ...